You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOxazepam
Accession NumberDB00842  (APRD01152)
TypeSmall Molecule
GroupsApproved
DescriptionOxazepam is an intermediate-acting benzodiazepine used to treat alcohol withdrawal and anxiety disorders. Oxazepam is also the metabolite of other benzodiazpines.
Structure
Thumb
Synonyms
(+-)-Oxazepam
(RS)-Oxazepam
Oxazepam
Serax
Tazepam
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bio-oxazepamtablet30 mgoralBiomed Pharma2003-04-23Not applicableCanada
Bio-oxazepamtablet10 mgoralBiomed Pharma2003-04-23Not applicableCanada
Bio-oxazepamtablet15 mgoralBiomed Pharma2003-04-23Not applicableCanada
Novoxapam Tab 10mgtablet10 mgoralNovopharm Limited1982-12-312015-10-26Canada
Novoxapam Tab 15mgtablet15 mgoralNovopharm Limited1982-12-312015-10-26Canada
Novoxapam Tab 30mgtablet30 mgoralNovopharm Limited1982-12-312015-10-26Canada
Oxazepam 10 Tab 10mgtablet10 mgoralPro Doc Limitee1980-12-31Not applicableCanada
Oxazepam 10mg Tabletstablet10 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Oxazepam 15 Tab 15mgtablet15 mgoralPro Doc Limitee1980-12-31Not applicableCanada
Oxazepam 15mg Tabletstablet15 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Oxazepam 30 Tab 30mgtablet30 mgoralPro Doc Limitee1980-12-31Not applicableCanada
Oxazepam 30mg Tabletstablet30 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Oxazepam Tablets 15mgtablet15 mgoralD.C. Labs Limited1980-12-312003-07-11Canada
Oxazepam Tablets 30mgtablet30 mgoralD.C. Labs Limited1980-12-312003-07-11Canada
Oxpamtablet10 mgoralBiomed Pharma1979-12-31Not applicableCanada
Oxpamtablet15 mgoralBiomed Pharma1979-12-31Not applicableCanada
Oxpamtablet30 mgoralBiomed Pharma1979-12-31Not applicableCanada
PMS-oxazepam Tab 10mgtablet10 mgoralPharmascience Inc1989-12-31Not applicableCanada
PMS-oxazepam Tab 15mgtablet15 mgoralPharmascience Inc1989-12-31Not applicableCanada
PMS-oxazepam Tab 30mgtablet30 mgoralPharmascience Inc1988-12-31Not applicableCanada
Riva Oxazepamtablet30 mgoralLaboratoire Riva Inc1983-12-31Not applicableCanada
Riva Oxazepamtablet10 mgoralLaboratoire Riva Inc1983-12-31Not applicableCanada
Riva Oxazepamtablet15 mgoralLaboratoire Riva Inc1983-12-31Not applicableCanada
Serax Tab 15mgtablet15 mgoralWyeth Ltd.1975-12-311996-09-10Canada
Serax Tab 30mgtablet30 mgoralWyeth Ltd.1972-12-311996-09-10Canada
Serax Tablets 10mgtablet10 mgoralWyeth Ayerst Canada Inc.1995-12-312001-05-07Canada
Serax Tablets 15mgtablet15 mgoralWyeth Ayerst Canada Inc.1994-12-312002-05-17Canada
Serax Tablets 30mgtablet30 mgoralWyeth Ayerst Canada Inc.1994-12-312001-10-29Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Oxazepam Tab 10mgtablet10 mgoralApotex Inc1979-12-31Not applicableCanada
Apo Oxazepam Tab 15mgtablet15 mgoralApotex Inc1979-12-31Not applicableCanada
Apo Oxazepam Tab 30mgtablet30 mgoralApotex Inc1979-12-31Not applicableCanada
Oxazepamcapsule, gelatin coated30 mg/1oralAphena Pharma Solutions Tennessee, Inc.2007-01-02Not applicableUs
Oxazepamcapsule, gelatin coated10 mg/1oralActavis Elizabeth LLC2007-01-02Not applicableUs
Oxazepamcapsule30 mg/1oralAmerican Health Packaging2013-07-05Not applicableUs
Oxazepamcapsule15 mg/1oralSandoz Inc1988-04-19Not applicableUs
Oxazepamcapsule10 mg/1oralREMEDYREPACK INC.2011-09-06Not applicableUs
Oxazepamcapsule, gelatin coated15 mg/1oralActavis Elizabeth LLC2007-01-02Not applicableUs
Oxazepamcapsule15 mg/1oralbryant ranch prepack2011-01-06Not applicableUs
Oxazepamcapsule30 mg/1oralSandoz Inc1988-04-19Not applicableUs
Oxazepamcapsule10 mg/1oralAmerican Health Packaging2013-07-05Not applicableUs
Oxazepamcapsule, gelatin coated30 mg/1oralActavis Elizabeth LLC2007-01-02Not applicableUs
Oxazepamcapsule, gelatin coated10 mg/1oralAphena Pharma Solutions Tennessee, Llc2007-01-02Not applicableUs
Oxazepamcapsule15 mg/1oralSTAT Rx USA LLC1988-04-14Not applicableUs
Oxazepamcapsule15 mg/1oralAmerican Health Packaging2013-07-05Not applicableUs
Oxazepamcapsule10 mg/1oralSandoz Inc1988-04-19Not applicableUs
Oxazepamcapsule, gelatin coated15 mg/1oralAphena Pharma Solutions Tennessee, Llc2007-01-02Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdumbranNot Available
AlepamNot Available
AlopamNot Available
AnxiolitNot Available
DurazepamNot Available
LimbialNot Available
MedopamNot Available
MurelaxNot Available
NoripamNot Available
OpamoxNot Available
Ox-PamNot Available
OxascandNot Available
PraxitenNot Available
PurataNot Available
SeraxLandsteiner (Mexico)
SerenalNot Available
SerenidNot Available
SerepaxNot Available
SerestaNot Available
SerpaxNot Available
SobrilNot Available
TazepamNot Available
VabenNot Available
ZaxpamNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII6GOW6DWN2A
CAS number604-75-1
WeightAverage: 286.713
Monoisotopic: 286.050905313
Chemical FormulaC15H11ClN2O2
InChI KeyInChIKey=ADIMAYPTOBDMTL-UHFFFAOYSA-N
InChI
InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19)
IUPAC Name
7-chloro-3-hydroxy-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzodiazepines
Sub Class1,4-benzodiazepines
Direct Parent1,4-benzodiazepines
Alternative Parents
Substituents
  • 1,4-benzodiazepine
  • Chlorobenzene
  • Benzenoid
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl chloride
  • Secondary carboxylic acid amide
  • Lactam
  • Ketimine
  • Carboxamide group
  • Azacycle
  • Organic 1,3-dipolar compound
  • Propargyl-type 1,3-dipolar organic compound
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Alkanolamine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Imine
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of anxiety disorders and alcohol withdrawal.
PharmacodynamicsOxazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation.
Mechanism of actionSimilar to other benzodiazepines, oxazepam exerts its anxiolytic effects by potentiating the effect of gamma-aminobutyric acid (GABA) on GABA-A receptors through a cooperative mechanism of action. GABA receptors are ionotropic chloride-linked channel receptors that produce inhibitory postsynaptic potentials. When activated by GABA, the GABA receptor/chloride ionophore complex undergoes a conformational change that allows the passage of chloride ions through the channel. Benzodiazepines are believed to exert their effect by increasing the effect of GABA at its receptor. Benzodiazepine binding increases chloride conductance in the presence of GABA by increasing the frequency at which the channel opens. In contrast, barbiturates increase chloride conductance in the presence of GABA by prolonging the time in which the channel remains open. There are 18 subtypes of the GABA receptor subunits. The α2 subunit of the α2β3γ2 receptor complex is thought to mediate anxiolytic effects while the α1 subunit of the α1β2γ2 receptor complex is thought to mediate sedative, anticonvulsant and anterograde amnesia effects.
Related Articles
AbsorptionWell absorbed from the gastrointestinal tract following oral administration however is absorbed at a slower rate compared to other benzodiazepines like diazepam or flurazepam. Time to peak concentration = 2-4 hours. Onset of action is slow, > 3 hours, following oral administration.
Volume of distributionNot Available
Protein binding80-99%
Metabolism

No active metabolites. It is hepatically metabolized and undergoes glucuronidation. The glucuronidation of the S-isomer is catalyzed by UGT2B15. The glucuronidation of the R-isomer is catalyzed by UGT2B7 and UGT1A9.

Route of eliminationThis product has a single, major inactive metabolite in man, a glucuronide excreted in the urine.
Half lifeMean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)
ClearanceNot Available
ToxicitySymptoms of overdose include confusion, drowsiness, and lethargy.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9826
Blood Brain Barrier+0.9641
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.517
P-glycoprotein inhibitor INon-inhibitor0.8866
P-glycoprotein inhibitor IINon-inhibitor0.9167
Renal organic cation transporterNon-inhibitor0.8812
CYP450 2C9 substrateNon-substrate0.7692
CYP450 2D6 substrateNon-substrate0.8685
CYP450 3A4 substrateSubstrate0.5631
CYP450 1A2 substrateInhibitor0.8262
CYP450 2C9 inhibitorNon-inhibitor0.5063
CYP450 2D6 inhibitorNon-inhibitor0.8445
CYP450 2C19 inhibitorInhibitor0.5065
CYP450 3A4 inhibitorNon-inhibitor0.6563
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6407
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7711
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8229 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.999
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Actavis elizabeth llc
  • American therapeutics inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Watson laboratories inc
  • Alpharma us pharmaceuticals division
  • Quantum pharmics ltd
  • Parke davis div warner lambert co
Packagers
Dosage forms
FormRouteStrength
Tabletoral10 mg
Tabletoral15 mg
Tabletoral30 mg
Capsuleoral10 mg/1
Capsuleoral15 mg/1
Capsuleoral30 mg/1
Capsule, gelatin coatedoral10 mg/1
Capsule, gelatin coatedoral15 mg/1
Capsule, gelatin coatedoral30 mg/1
Prices
Unit descriptionCostUnit
Oxazepam 30 mg capsule1.2USD capsule
Serax 10 mg capsule1.17USD capsule
Oxazepam 15 mg capsule0.73USD capsule
Oxazepam 10 mg capsule0.6USD capsule
Apo-Oxazepam 30 mg Tablet0.09USD tablet
Apo-Oxazepam 15 mg Tablet0.07USD tablet
Apo-Oxazepam 10 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point205-206 °CPhysProp
water solubility179 mg/LNot Available
logP2.24HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0881 mg/mLALOGPS
logP2.01ALOGPS
logP2.92ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)10.61ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area61.69 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity77.89 m3·mol-1ChemAxon
Polarizability28.38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-05r0-5590000000-87245820addec0215473View in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Peppers MP: Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy. 1996 Jan-Feb;16(1):49-57. [PubMed:8700792 ]
  2. Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. [PubMed:6135616 ]
  3. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451 ]
  4. Christensen P, Lolk A, Gram LF, Kragh-Sorensen P: Benzodiazepine-induced sedation and cortisol suppression. A placebo-controlled comparison of oxazepam and nitrazepam in healthy male volunteers. Psychopharmacology (Berl). 1992;106(4):511-6. [PubMed:1349754 ]
  5. Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine]. Arch Fr Pediatr. 1977 Jan;34(1):74-89. [PubMed:851373 ]
  6. Altamura AC, Moliterno D, Paletta S, Maffini M, Mauri MC, Bareggi S: Understanding the pharmacokinetics of anxiolytic drugs. Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):423-40. doi: 10.1517/17425255.2013.759209. Epub 2013 Jan 21. [PubMed:23330992 ]
External Links
ATC CodesN05BA04
AHFS Codes
  • 28:24.08
PDB EntriesNot Available
FDA labelDownload (356 KB)
MSDSDownload (44.2 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Oxazepam is combined with 7-Nitroindazole.
AcepromazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Oxazepam is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Oxazepam.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxazepam.
AminophyllineThe therapeutic efficacy of Oxazepam can be decreased when used in combination with Aminophylline.
AmiodaroneThe metabolism of Oxazepam can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amitriptyline.
AmobarbitalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amperozide.
AprepitantThe serum concentration of Oxazepam can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Oxazepam is combined with Aripiprazole.
ArticaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Asenapine.
AtazanavirThe metabolism of Oxazepam can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Oxazepam can be decreased when combined with Atomoxetine.
AzaperoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Azaperone.
AzelastineOxazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Oxazepam.
BaclofenThe risk or severity of adverse effects can be increased when Oxazepam is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Barbital.
BenzocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Oxazepam is combined with Benzyl alcohol.
BexaroteneThe serum concentration of Oxazepam can be decreased when it is combined with Bexarotene.
BoceprevirThe metabolism of Oxazepam can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Oxazepam can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Oxazepam can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Oxazepam is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.
BrimonidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Brotizolam.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Oxazepam.
BuprenorphineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxazepam.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxazepam.
ButacaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Oxazepam is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Oxazepam.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Oxazepam.
CarbinoxamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Oxazepam is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Carisoprodol.
CeritinibThe serum concentration of Oxazepam can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxazepam.
ChlormezanoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chloroprocaine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Oxazepam.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorzoxazone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Oxazepam.
CitalopramThe risk or severity of adverse effects can be increased when Oxazepam is combined with Citalopram.
ClarithromycinThe metabolism of Oxazepam can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Oxazepam can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Oxazepam is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxazepam.
ClotrimazoleThe metabolism of Oxazepam can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Oxazepam.
CobicistatThe metabolism of Oxazepam can be decreased when combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Oxazepam.
ConivaptanThe serum concentration of Oxazepam can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Oxazepam can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Oxazepam can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cyproheptadine.
DabrafenibThe serum concentration of Oxazepam can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Oxazepam.
DapoxetineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dapoxetine.
DarunavirThe metabolism of Oxazepam can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Oxazepam can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Oxazepam can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Oxazepam can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Oxazepam is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Detomidine.
DexamethasoneThe serum concentration of Oxazepam can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Oxazepam.
DextromoramideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Oxazepam.
DezocineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Oxazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Oxazepam can be decreased when combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dihydromorphine.
DiltiazemThe metabolism of Oxazepam can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Diphenoxylate.
DoramectinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Doxepin.
DoxycyclineThe metabolism of Oxazepam can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.
DoxylamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Oxazepam is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.
DronedaroneThe metabolism of Oxazepam can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Oxazepam.
DrotebanolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Oxazepam.
DyphyllineThe therapeutic efficacy of Oxazepam can be decreased when used in combination with Dyphylline.
EcgonineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Oxazepam is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Oxazepam can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Oxazepam is combined with Efavirenz.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Oxazepam.
EntacaponeThe risk or severity of adverse effects can be increased when Oxazepam is combined with Entacapone.
EnzalutamideThe serum concentration of Oxazepam can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Oxazepam can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Oxazepam is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Oxazepam can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxazepam.
EthanolOxazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Oxazepam.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Oxazepam.
EthosuximideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxazepam.
EtoperidoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Etorphine.
EtravirineThe serum concentration of Oxazepam can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxazepam.
FexofenadineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flibanserin.
FluconazoleThe metabolism of Oxazepam can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluvoxamine.
FluvoxamineThe metabolism of Oxazepam can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Oxazepam can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Oxazepam can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Oxazepam.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Oxazepam.
FospropofolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fospropofol.
Fusidic AcidThe serum concentration of Oxazepam can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Oxazepam is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Oxazepam is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Oxazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Oxazepam.
HalothaneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Hexobarbital.
HydrocodoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxazepam.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.
HydroxyzineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Hydroxyzine.
IdelalisibThe serum concentration of Oxazepam can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Iloperidone.
ImatinibThe metabolism of Oxazepam can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Indalpine.
IndinavirThe metabolism of Oxazepam can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Oxazepam can be decreased when combined with Isavuconazonium.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Oxazepam.
IsradipineThe metabolism of Oxazepam can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Oxazepam can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Oxazepam can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ketobemidone.
KetoconazoleThe metabolism of Oxazepam can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Oxazepam.
LithiumThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lofentanil.
LopinavirThe metabolism of Oxazepam can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxazepam.
LovastatinThe metabolism of Oxazepam can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxazepam.
Lu AA21004The risk or severity of adverse effects can be increased when Oxazepam is combined with Lu AA21004.
LuliconazoleThe serum concentration of Oxazepam can be increased when it is combined with Luliconazole.
LurasidoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Oxazepam is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxazepam.
MesoridazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Metaxalone.
MethadoneOxazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Oxazepam.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxazepam.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methylphenobarbital.
MetyrosineOxazepam may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxazepam.
MifepristoneThe metabolism of Oxazepam can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Oxazepam is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.
MirtazapineOxazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Oxazepam.
MitotaneThe serum concentration of Oxazepam can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Oxazepam can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Oxazepam.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.
NabiloneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nabilone.
NafcillinThe serum concentration of Oxazepam can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nalbuphine.
NefazodoneThe metabolism of Oxazepam can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Oxazepam can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Oxazepam can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Oxazepam can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Oxazepam can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxazepam.
OlaparibThe metabolism of Oxazepam can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Oxazepam is combined with Opium.
OrphenadrineOxazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Oxazepam.
OsanetantThe risk or severity of adverse effects can be increased when Oxazepam is combined with Osanetant.
OsimertinibThe serum concentration of Oxazepam can be increased when it is combined with Osimertinib.
OxprenololThe risk or severity of adverse effects can be increased when Oxazepam is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxazepam.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Oxymorphone.
PalbociclibThe serum concentration of Oxazepam can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Paliperidone.
ParaldehydeOxazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Oxazepam.
ParoxetineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxazepam.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Oxazepam.
PerampanelThe risk or severity of adverse effects can be increased when Oxazepam is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Oxazepam is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxazepam.
PhenobarbitalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Phenoxyethanol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Oxazepam.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Oxazepam.
PimozideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pimozide.
PipamperoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pomalidomide.
PosaconazoleThe metabolism of Oxazepam can be decreased when combined with Posaconazole.
PramipexoleOxazepam may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Oxazepam.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Oxazepam.
PrimidoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Oxazepam.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxazepam.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Oxazepam.
PromethazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Oxazepam.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Oxazepam.
PropoxycaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Propoxycaine.
ProtriptylineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Oxazepam is combined with PSD502.
QuazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Quetiapine.
RamelteonThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ramelteon.
RanolazineThe metabolism of Oxazepam can be decreased when combined with Ranolazine.
RemifentanilThe risk or severity of adverse effects can be increased when Oxazepam is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Oxazepam.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxazepam.
RifabutinThe metabolism of Oxazepam can be increased when combined with Rifabutin.
RifampicinThe metabolism of Oxazepam can be increased when combined with Rifampicin.
RifapentineThe metabolism of Oxazepam can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxazepam.
RitonavirThe metabolism of Oxazepam can be decreased when combined with Ritonavir.
RomifidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Romifidine.
RopiniroleOxazepam may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Oxazepam.
RotigotineOxazepam may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Oxazepam.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Oxazepam is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Oxazepam can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxazepam.
SertindoleThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sevoflurane.
SildenafilThe metabolism of Oxazepam can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Oxazepam can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Oxazepam can be increased when it is combined with Simeprevir.
Sodium oxybateOxazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Oxazepam.
St. John's WortThe serum concentration of Oxazepam can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxazepam.
SulfisoxazoleThe metabolism of Oxazepam can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Oxazepam.
SuvorexantThe risk or severity of adverse effects can be increased when Oxazepam is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tasimelteon.
TeduglutideThe serum concentration of Oxazepam can be increased when it is combined with Teduglutide.
TelaprevirThe metabolism of Oxazepam can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Oxazepam can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxazepam.
TetrabenazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tetrodotoxin.
ThalidomideOxazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Oxazepam.
TheophyllineThe therapeutic efficacy of Oxazepam can be decreased when used in combination with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Oxazepam.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Oxazepam.
ThiothixeneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tiagabine.
TiclopidineThe metabolism of Oxazepam can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tiletamine.
TizanidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tizanidine.
TocilizumabThe serum concentration of Oxazepam can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxazepam.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Oxazepam.
TrazodoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxazepam.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Oxazepam.
TrimipramineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Oxazepam.
VenlafaxineThe metabolism of Oxazepam can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Oxazepam can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Vilazodone.
VoriconazoleThe metabolism of Oxazepam can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Xylazine.
YohimbineThe therapeutic efficacy of Oxazepam can be decreased when used in combination with Yohimbine.
ZaleplonThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zimelidine.
ZiprasidoneThe metabolism of Oxazepam can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Oxazepam.
ZonisamideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA2
Uniprot ID:
P47869
Molecular Weight:
51325.85 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA3
Uniprot ID:
P34903
Molecular Weight:
55164.055 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA4
Uniprot ID:
P48169
Molecular Weight:
61622.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transporter activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA5
Uniprot ID:
P31644
Molecular Weight:
52145.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRA6
Uniprot ID:
Q16445
Molecular Weight:
51023.69 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRB1
Uniprot ID:
P18505
Molecular Weight:
54234.085 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB2
Uniprot ID:
P47870
Molecular Weight:
59149.895 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-gated chloride ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRB3
Uniprot ID:
P28472
Molecular Weight:
54115.04 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG1
Uniprot ID:
Q8N1C3
Molecular Weight:
53594.49 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel.
Gene Name:
GABRG2
Uniprot ID:
P18507
Molecular Weight:
54161.78 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRG3
Uniprot ID:
Q99928
Molecular Weight:
54288.16 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRD
Uniprot ID:
O14764
Molecular Weight:
50707.835 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRE
Uniprot ID:
P78334
Molecular Weight:
57971.175 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the uterus, the function of the receptor appears to be related to tissue contractility. The binding of this pI subunit with other GABA(A) receptor subunits alters the sensitivity of recombinant receptors to ...
Gene Name:
GABRP
Uniprot ID:
O00591
Molecular Weight:
50639.735 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR1
Uniprot ID:
P24046
Molecular Weight:
55882.91 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA receptor could play a role in retinal neurotransmission.
Gene Name:
GABRR2
Uniprot ID:
P28476
Molecular Weight:
54150.41 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Gaba-a receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRR3
Uniprot ID:
A8MPY1
Molecular Weight:
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Transmembrane signaling receptor activity
Specific Function:
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name:
GABRQ
Uniprot ID:
Q9UN88
Molecular Weight:
72020.875 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090 ]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Monooxygenase activity
Specific Function:
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name:
CYP3A43
Uniprot ID:
Q9HB55
Molecular Weight:
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme displays activity toward several classes of xenobiotic substrates, including simple phenolic compounds, 7-hydroxylated coumarins, flavonoids, anthraquinones, and certain drugs and their hydroxylated metabolites. It also catalyzes the glucuronidatio...
Gene Name:
UGT2B15
Uniprot ID:
P54855
Molecular Weight:
61035.815 Da
References
  1. Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL, Greenblatt DJ: Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos. 2002 Nov;30(11):1257-65. [PubMed:12386133 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL, Greenblatt DJ: Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos. 2002 Nov;30(11):1257-65. [PubMed:12386133 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL, Greenblatt DJ: Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos. 2002 Nov;30(11):1257-65. [PubMed:12386133 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23